Table 2

Respiratory support and medications received pre-discharge

Number of infantsStarting age (days)Starting CGA (weeks)Total duration
(days)
Postnatal age last received (days)
Respiratory support
Invasive ventilation91/92 (98.9%)0 (0–0; 0–2)26.4 (24.6–28.1; 23.3–31.3)29 (17–51; 1–238)50 (22–98)
Nasal CPAP/BiPAP89/92 (96.7%)20 (6–39; 0–152)29.6 (27.7–32.1; 24.3–48.7)27 (14–45; 2–297)84 (49–103)
Nasal high flow84/92 (91.3%)49.5 (28–84; 0–161)33.6 (31.1–37.1; 27.7–50.7)40.5 (22–64; 4–156)109 (89.5–143)
Medications
PDA closure36/94 (38.6%)7.5 (5–14.5; 0–34)26.3 (25.3–27.1; 23.9–31.9)
 Ibuprofen33 (91.7%)
 Paracetamol4 (11.1%)
Postnatal steroid57/94 (60.6%)26 (14–48; 0–185)29.7 (27.9–33.4; 24.6–55.9)23 (14–44)91 (57–150)
Diuretics82/94 (87.2%)32 (17–51; 3–204)31.1 (29.1–34.5; 25.4–34.5)90 (49–123)128 (101–169)
Inhaled steroid16/94 (17.0%)96.5 (60–126; 9–231)39.4 (35.0–46.5; 26.4–61.1)21 (5–74)132 (104–183)
Inhaled bronchodilators8/94 (8.5%)124.5 (120–192; 100–231)45.4 (42.4–56.6; 40.9–61.1)14 (5–27)148 (134–209)
Sildenafil22/94 (23.4%)44 (18–132)
  • Data presented as number (%) or median (IQR; ±range). Ages and duration displayed for infants who received intervention only.

  • BiPAP, bilevel positive airway pressure; CGA, corrected gestational age; CPAP, continuous positive airway pressure; PDA, patent ductus arteriosus.